![Idina Shi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Idina Shi currently works as an Operations Director & Business Development professional at Nuevocor Pte Ltd.
Actieve functies van Idina Shi
Bedrijven | Functie | Begin |
---|---|---|
Nuevocor Pte Ltd.
![]() Nuevocor Pte Ltd. Pharmaceuticals: MajorHealth Technology Nuevocor Pte Ltd. is a biotechnology company based in Singapore, Singapore. The Singaporean company pioneers an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases by harnessing their Prosia mechanobiology platform. The company's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables them to extend their impact to broader patient populations. The company was founded by Colin Stewart, Mark Kay, Jianming Jiang, Yin Loon Lee, Tan Yann Chong, Brian Burke. Tan Yann Chong has been the CEO since incorporation. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Nuevocor Pte Ltd.
![]() Nuevocor Pte Ltd. Pharmaceuticals: MajorHealth Technology Nuevocor Pte Ltd. is a biotechnology company based in Singapore, Singapore. The Singaporean company pioneers an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases by harnessing their Prosia mechanobiology platform. The company's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables them to extend their impact to broader patient populations. The company was founded by Colin Stewart, Mark Kay, Jianming Jiang, Yin Loon Lee, Tan Yann Chong, Brian Burke. Tan Yann Chong has been the CEO since incorporation. | Health Technology |